BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong M, Clubb JD, Chen YY. Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell 2020;38:473-88. [DOI: 10.1016/j.ccell.2020.07.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 22.5] [Reference Citation Analysis]
Number Citing Articles
1 Ahn S, Leblay N, Neri P. Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma. Hemasphere 2021;5:e575. [PMID: 34095759 DOI: 10.1097/HS9.0000000000000575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cai W, Dong J, Gallolu Kankanamalage S, Titong A, Shi J, Jia Z, Wang B, Huang C, Zhang J, Lin J, Kan SZ, Han S, Zhou J, Liu Y. Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action. Antib Ther 2021;4:228-41. [PMID: 34805746 DOI: 10.1093/abt/tbab024] [Reference Citation Analysis]
3 Cao W, Geng ZZ, Wang N, Pan Q, Guo S, Xu S, Zhou J, Liu WR. A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**. Angewandte Chemie. [DOI: 10.1002/ange.202109550] [Reference Citation Analysis]
4 Tauriello DVF, Sancho E, Batlle E. Overcoming TGFβ-mediated immune evasion in cancer. Nat Rev Cancer 2021. [PMID: 34671117 DOI: 10.1038/s41568-021-00413-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med 2021;25:9891-904. [PMID: 34585512 DOI: 10.1111/jcmm.16939] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 [DOI: 10.1101/2020.10.01.322990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
8 Abken H. Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. Hum Gene Ther 2021;32:1011-28. [PMID: 34405686 DOI: 10.1089/hum.2021.165] [Reference Citation Analysis]
9 Li JH, Chen YY. A Fresh Approach to Targeting Aging Cells: CAR-T Cells Enhance Senolytic Specificity. Cell Stem Cell 2020;27:192-4. [PMID: 32763179 DOI: 10.1016/j.stem.2020.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Li X, Han QC, Yu C, Luo YC, Wang F, Sun XH, Gao YQ, Tan WF, Xia Q. C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment. J Dig Dis 2021;22:433-41. [PMID: 33978316 DOI: 10.1111/1751-2980.12997] [Reference Citation Analysis]
11 Molina JC, Shah NN. CAR T cells better than BiTEs. Blood Adv 2021;5:602-6. [PMID: 33496756 DOI: 10.1182/bloodadvances.2020003554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chandler NJ, Call MJ, Call ME. T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors. Int J Mol Sci 2020;21:E7424. [PMID: 33050044 DOI: 10.3390/ijms21197424] [Reference Citation Analysis]
13 Abrantes R, Duarte HO, Gomes C, Wälchli S, Reis CA. CAR-Ts: new perspectives in cancer therapy. FEBS Lett 2022. [PMID: 34978080 DOI: 10.1002/1873-3468.14270] [Reference Citation Analysis]
14 Davies DM, Maher J. Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells. Cancer Cell 2021;39:138-40. [PMID: 33417830 DOI: 10.1016/j.ccell.2020.12.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Thomas P, Galopin N, Bonérandi E, Clémenceau B, Fougeray S, Birklé S. CAR T Cell Therapy's Potential for Pediatric Brain Tumors. Cancers (Basel) 2021;13:5445. [PMID: 34771608 DOI: 10.3390/cancers13215445] [Reference Citation Analysis]
16 Wang M, Zhang C, Jiang X. CAR-T: a potential gene carrier targeting solid tumor immune microenvironment. Signal Transduct Target Ther 2021;6:393. [PMID: 34764238 DOI: 10.1038/s41392-021-00812-z] [Reference Citation Analysis]
17 Kruyer NS, Sugianto W, Tickman BI, Alba Burbano D, Noireaux V, Carothers JM, Peralta-Yahya P. Membrane Augmented Cell-Free Systems: A New Frontier in Biotechnology. ACS Synth Biol 2021;10:670-81. [PMID: 33749249 DOI: 10.1021/acssynbio.0c00625] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Wei J, Zheng W, Chapman NM, Geiger TL, Chi H. T cell metabolism in homeostasis and cancer immunity. Curr Opin Biotechnol 2021;68:240-50. [PMID: 33676144 DOI: 10.1016/j.copbio.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Qin VM, D'Souza C, Neeson PJ, Zhu JJ. Chimeric Antigen Receptor beyond CAR-T Cells. Cancers (Basel) 2021;13:404. [PMID: 33499101 DOI: 10.3390/cancers13030404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Yang Y, Liu L, Guo Z, Huang J, Li L, Shao Y, Song M, Yang A, Sun B. A novel computer vision-based assessment of neutrophil chemotaxis in patients with severe infection. Clin Transl Immunology 2021;10:e1333. [PMID: 34434554 DOI: 10.1002/cti2.1333] [Reference Citation Analysis]
21 Voigt CA. Synthetic biology 2020-2030: six commercially-available products that are changing our world. Nat Commun 2020;11:6379. [PMID: 33311504 DOI: 10.1038/s41467-020-20122-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
22 Manhas J, Edelstein HI, Leonard JN, Morsut L. The evolution of synthetic receptor systems. Nat Chem Biol. [DOI: 10.1038/s41589-021-00926-z] [Reference Citation Analysis]
23 Chen XH, Chen R, Shi MY, Tian RF, Zhang H, Xin ZQ, Chen ZN, Wang K. Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. Transl Oncol 2021;16:101309. [PMID: 34896852 DOI: 10.1016/j.tranon.2021.101309] [Reference Citation Analysis]
24 Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists. J Am Acad Dermatol 2021:S0190-9622(21)02144-7. [PMID: 34293386 DOI: 10.1016/j.jaad.2021.07.017] [Reference Citation Analysis]
25 Ruggeri B. Cancer 2021: New therapeutic approaches for the treatment of cancer - building on advances in cancer biology and the molecular genetics of cancer. Curr Opin Pharmacol 2021;60:341-5. [PMID: 34534753 DOI: 10.1016/j.coph.2021.08.010] [Reference Citation Analysis]
26 Zhao L, Ren L, Gao S, Wang J, Li X, Zhang L, Zhu Y, Li H. Tumor immunology in the age of single-cell genomics. J Leukoc Biol 2021. [PMID: 34184318 DOI: 10.1002/JLB.5MR0321-170R] [Reference Citation Analysis]
27 León-Triana O, Pérez-Martínez A, Ramírez-Orellana M, Pérez-García VM. Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers (Basel) 2021;13:703. [PMID: 33572301 DOI: 10.3390/cancers13040703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Lebrec H, Maier CC, Maki K, Ponce R, Shenton J, Green S. Nonclinical safety assessment of engineered T cell therapies. Regul Toxicol Pharmacol 2021;127:105064. [PMID: 34656748 DOI: 10.1016/j.yrtph.2021.105064] [Reference Citation Analysis]
29 Yang Y, Wang K, Pan Y, Rao L, Luo G. Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation. Adv Sci (Weinh) 2021;:e2102330. [PMID: 34693653 DOI: 10.1002/advs.202102330] [Reference Citation Analysis]
30 Shelton SE, Nguyen HT, Barbie DA, Kamm RD. Engineering approaches for studying immune-tumor cell interactions and immunotherapy. iScience 2021;24:101985. [PMID: 33490895 DOI: 10.1016/j.isci.2020.101985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
31 Tang Y, Zhang AXJ, Chen G, Wu Y, Gu W. Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives. Mol Ther Oncolytics 2021;22:410-30. [PMID: 34553029 DOI: 10.1016/j.omto.2021.07.006] [Reference Citation Analysis]
32 Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ Jr, Melenhorst JJ. Engineering enhanced CAR T-cells for improved cancer therapy. Nat Cancer 2021;2:780-93. [PMID: 34485921 DOI: 10.1038/s43018-021-00241-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kharfan-Dabaja MA, Yassine F, Gadd ME, Qin H. Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. Transplant Cell Ther 2021:S2666-6367(21)01297-5. [PMID: 34656807 DOI: 10.1016/j.jtct.2021.10.005] [Reference Citation Analysis]
34 Chu W, Prodromou R, Day KN, Schneible JD, Bacon KB, Bowen JD, Kilgore RE, Catella CM, Moore BD, Mabe MD, Alashoor K, Xu Y, Xiao Y, Menegatti S. Peptides and pseudopeptide ligands: a powerful toolbox for the affinity purification of current and next-generation biotherapeutics. J Chromatogr A 2021;1635:461632. [PMID: 33333349 DOI: 10.1016/j.chroma.2020.461632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wang H, Wang L, Li Y, Li G, Zhang X, Jiang D, Zhang Y, Liu L, Chu Y, Xu G. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells. Cancer Cell Int 2021;21:450. [PMID: 34429118 DOI: 10.1186/s12935-021-02151-z] [Reference Citation Analysis]
36 Toulouie S, Johanning G, Shi Y. Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges. J Cancer 2021;12:1212-9. [PMID: 33442419 DOI: 10.7150/jca.54095] [Reference Citation Analysis]
37 Jing Y, Liu Y, Li Q, Ye Y, Diao L, Huang Y, Zhou Y, Green MR, Mills GB, Han L. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell 2021:S1535-6108(21)00505-5. [PMID: 34678153 DOI: 10.1016/j.ccell.2021.09.016] [Reference Citation Analysis]
38 Rurik JG, Aghajanian H, Epstein JA. Immune Cells and Immunotherapy for Cardiac Injury and Repair. Circ Res 2021;128:1766-79. [PMID: 34043424 DOI: 10.1161/CIRCRESAHA.121.318005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Goydel RS, Rader C. Antibody-based cancer therapy. Oncogene 2021;40:3655-64. [PMID: 33947958 DOI: 10.1038/s41388-021-01811-8] [Reference Citation Analysis]
40 Hamilton G, Plangger A. The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. Biologics 2021;15:265-77. [PMID: 34262255 DOI: 10.2147/BTT.S290305] [Reference Citation Analysis]
41 Liu S, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther 2021;6:8. [PMID: 33414388 DOI: 10.1038/s41392-020-00436-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
42 Duan Y, Chen R, Huang Y, Meng X, Chen J, Liao C, Tang Y, Zhou C, Gao X, Sun J. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci 2021;79:14. [PMID: 34966954 DOI: 10.1007/s00018-021-04089-x] [Reference Citation Analysis]
43 Yuan Y, Fu Q, Zhang Y, Xu D, Wu Y, Qiu Q, Zhou W. CAR-based cell therapy: evaluation with bibliometrics and patent analysis. Hum Vaccin Immunother 2021;:1-9. [PMID: 34184975 DOI: 10.1080/21645515.2021.1947100] [Reference Citation Analysis]
44 Javdan SB, Deans TL. Design and development of engineered receptors for cell and tissue engineering. Curr Opin Syst Biol 2021;28:100363. [PMID: 34527831 DOI: 10.1016/j.coisb.2021.100363] [Reference Citation Analysis]
45 Xu X, Huang S, Xiao X, Sun Q, Liang X, Chen S, Zhao Z, Huo Z, Tu S, Li Y. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Front Immunol 2020;11:569117. [PMID: 33643279 DOI: 10.3389/fimmu.2020.569117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Li Y, Li JQ, Jiang HP, Li X. The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer. Dis Markers 2021;2021:5669635. [PMID: 34777633 DOI: 10.1155/2021/5669635] [Reference Citation Analysis]
47 Lin Z, Wu Z, Luo W. A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy. Front Immunol 2021;12:707211. [PMID: 34566963 DOI: 10.3389/fimmu.2021.707211] [Reference Citation Analysis]
48 Špilak A, Brachner A, Kegler U, Neuhaus W, Noehammer C. Implications and pitfalls for cancer diagnostics exploiting extracellular vesicles. Adv Drug Deliv Rev 2021;175:113819. [PMID: 34087328 DOI: 10.1016/j.addr.2021.05.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Pinte L, Cunningham A, Trébéden-Negre H, Nikiforow S, Ritz J. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol 2020;11:608485. [PMID: 33658994 DOI: 10.3389/fimmu.2020.608485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Hong M, Chen YY. Killer fatigue: Transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion. Cell 2021;184:6017-9. [PMID: 34890549 DOI: 10.1016/j.cell.2021.11.015] [Reference Citation Analysis]
51 Liang JL, Luo GF, Chen WH, Zhang XZ. Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy. Adv Mater 2021;33:e2007630. [PMID: 34050564 DOI: 10.1002/adma.202007630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 McNerney MP, Doiron KE, Ng TL, Chang TZ, Silver PA. Theranostic cells: emerging clinical applications of synthetic biology. Nat Rev Genet 2021. [PMID: 34234299 DOI: 10.1038/s41576-021-00383-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Arévalo-Soliz LM, Hardee CL, Fogg JM, Corman NR, Noorbakhsh C, Zechiedrich L. Improving therapeutic potential of non-viral minimized DNA vectors. Cell Gene Ther Insights 2020;6:1489-505. [PMID: 33953961 DOI: 10.18609/cgti.2020.163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Chen Z, Elowitz MB. Programmable protein circuit design. Cell 2021;184:2284-301. [PMID: 33848464 DOI: 10.1016/j.cell.2021.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wang S, Sun F, Huang H, Chen K, Li QJ, Zhang L, Wang E, Wang C, Zhang H, Yuan AQ, Chen B, Deng T, Liu Y, Sun J, Liu D, Yu Y, Fang Y, Jiang N, Wu D, Fang H, Bai Y, Xing S, Ni Y, Fan Q, Yu A, Sun C, Tang Y, Li N, Xu B, He J. The Landscape of Cell and Gene Therapies for Solid Tumors. Cancer Cell 2021;39:7-8. [PMID: 33434513 DOI: 10.1016/j.ccell.2020.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lv T, Zhao Y, Jiang X, Yuan H, Wang H, Cui X, Xu J, Zhao J, Wang J. uPAR: An Essential Factor for Tumor Development. J Cancer 2021;12:7026-40. [PMID: 34729105 DOI: 10.7150/jca.62281] [Reference Citation Analysis]
57 Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM, Yu BT, Wu N. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Front Immunol 2021;12:782775. [PMID: 34790207 DOI: 10.3389/fimmu.2021.782775] [Reference Citation Analysis]
58 Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res 2021;9:62. [PMID: 34332618 DOI: 10.1186/s40364-021-00316-6] [Reference Citation Analysis]
59 Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu XH. The Application of Nanobody in CAR-T Therapy. Biomolecules 2021;11:238. [PMID: 33567640 DOI: 10.3390/biom11020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lu SJ, Feng Q. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients. Stem Cells Transl Med 2021;10 Suppl 2:S10-7. [PMID: 34724715 DOI: 10.1002/sctm.21-0135] [Reference Citation Analysis]
61 Wehrli M, Maus MV. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Curr Opin Pharmacol 2021;59:116-26. [PMID: 34198161 DOI: 10.1016/j.coph.2021.05.005] [Reference Citation Analysis]